SEARCH RESULTS

300519 RESULTS

PAPER Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TL, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.

JAMA Neurol. 2023 Dec 1;80(12):1353-1363. PubMed.

Not So Fast—The Brain Has Three Meningeal Membranes After All

RESEARCH NEWS 2023-09-29 Research News Earlier this year, a high-profile Science paper caused a stir with its claim that the brain has a fourth, previously unrecognized, meningeal membrane. Dubbed SLYM and containing Prox1+ cells, this membrane was proposed to divide the subarach

Organization of Aβ Plaques and Tau Tangles Illuminated in AD Brain

RESEARCH NEWS 2023-08-10 Research News Just as the Hubble space telescope’s ultra-deep field illuminated thousands of galaxies swirling within a tiny, dark, patch of the sky, the cryo-electron microscope has unveiled a striking array of Aβ and tau structures, all inhabiting one t

Shrunken FDA Advisory Committee Is Unanimous: Leqembi Works

COMMUNITY NEWS 2023-06-09 Community News A Food and Drug Administration advisory committee today recommended traditional approval of Eisai’s anti-amyloid antibody lecanemab. On the sole voting question before it, the six-member committee unanimously agreed that lecanemab’s Phase 3

And Then There Were Three: Donanemab Phase 3 Trial Positive

RESEARCH NEWS 2023-05-04 Research News Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly press release. The treatment slowed decline

Legacy of A4 Secondary Prevention Study Goes Beyond Negative Result

RESEARCH NEWS 2023-03-17 Research News The decade-long Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study wrapped up this month. According to top-line results announced March 8 by Eli Lilly, more than four years of treatment with the anti-amyloid antibody solan

No Easy Answers on Clinical Meaningfulness of Alzheimer’s Treatments

RESEARCH NEWS 2023-02-16 Research News The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report from a working group convened by the Alzheim

No Accelerated Approval for Donanemab

RESEARCH NEWS 2023-01-20 Research News In a move that surprised many, the Food and Drug Administration has rejected Eli Lilly’s application for accelerated approval for its anti-amyloid antibody donanemab. The agency said there was not enough safety data, given that fewer than 10

DNL919

THERAPEUTICS Denali Therapeutics Inc. Takeda Pharmaceutical Company TAK-920 ATV:TREM2 Immunotherapy (passive) Amyloid-Related Inflammation In January 2022, the FDA placed a clinical hold on Denali’s investigational new drug application for DNL919 in the U.S., pending

And Then There Were Four: A New Meningeal Membrane Discovered

RESEARCH NEWS 2023-01-10 Research News Time to rewrite the brain anatomy textbook? In addition to the outermost dura, middle arachnoid, and innermost pia membranes surrounding the brain, researchers led by Kjeld Møllgård, University of Copenhagen, and Maiken Nedergaard, Universit

Dare We Say Consensus Achieved: Lecanemab Slows the Disease

CONFERENCE COVERAGE 2022-12-09 Conference Coverage The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement. Now they have. At the 15th Clinical T

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE